0001104659-24-022575.txt : 20240213
0001104659-24-022575.hdr.sgml : 20240213
20240213214839
ACCESSION NUMBER: 0001104659-24-022575
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240209
FILED AS OF DATE: 20240213
DATE AS OF CHANGE: 20240213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rondoni John
CENTRAL INDEX KEY: 0001932219
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38468
FILM NUMBER: 24631666
MAIL ADDRESS:
STREET 1: C/O INSPIRE MEDICAL SYSTEMS, INC.
STREET 2: 9700 63RD AVENUE NORTH, SUITE 200
CITY: MAPLE GROVE
STATE: MN
ZIP: 55369
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inspire Medical Systems, Inc.
CENTRAL INDEX KEY: 0001609550
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 261377674
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 WAYZATA BLVD
STREET 2: SUITE 1600
CITY: GOLDEN VALLEY
STATE: MN
ZIP: 55416
BUSINESS PHONE: 763-957-5037
MAIL ADDRESS:
STREET 1: 5500 WAYZATA BLVD
STREET 2: SUITE 1600
CITY: GOLDEN VALLEY
STATE: MN
ZIP: 55416
4
1
tm245999-7_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-02-09
0
0001609550
Inspire Medical Systems, Inc.
INSP
0001932219
Rondoni John
C/O INSPIRE MEDICAL SYSTEMS, INC.
5500 WAYZATA BLVD., SUITE 1600
GOLDEN VALLEY
MN
55416
0
1
0
0
Chief Technology Officer
0
Common Stock
2024-02-09
4
A
0
2694
0.00
A
16262
D
Employee Stock Option (Right to Buy)
194.87
2024-02-09
4
A
0
4376
0.00
A
2034-02-09
Common Stock
4376
4376
D
Represents an award of restricted stock units, which vests in three equal annual installments commencing on February 9, 2025. Each restricted stock unit represents acontingent right to receive one share of Issuer's common stock, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Includes (i) 58 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "Plan") on June 30, 2023 and (ii) 32 shares acquired under the Plan onDecember 31, 2023.
The option vests and becomes exercisable as to 25% of the underlying shares on February 9, 2025. The remaining 75% of the underlying shares will vest and becomeexercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
/s/ Bryan Phillips, Attorney-in-Fact for John Rondoni
2024-02-13